Skip to main content
. 2017 Oct 30;98(1):227–230. doi: 10.4269/ajtmh.17-0633

Table 1.

Characteristics of male patients with melioidosis prostatic abscess and male patients with melioidosis without prostatic abscess

Number All Men with prostatic abscess, N = 22 Men without prostatic abscess, N = 122 P value
Age (years) 144 54 (44-65) 56 (46–64) 54 (44–65) 0.51
Identifies as an ATSI 144 67 (47%) 12 (55%) 55 (45%) 0.49
Diabetes mellitus 142 76 (54%) 9 (41%) 67/120 (56%) 0.2
Hazardous alcohol intake* 139 76 (55%) 15/20 (75%) 61/119 (52%) 0.048
Chronic kidney disease 142 26 (18%) 2 (9%) 24/120 (21%) 0.22
Chronic lung disease 141 24 (17%) 2/21 (10%) 22/120 (18%) 0.32
Immunosuppressio§ 141 12 (9%) 0/21 (0%) 12/120 (10%) 0.13
Malignancy 141 14 (10%) 2/21 (9%) 12/120 (10%) 0.95
Urinary symptoms 134 40 (30%) 18 (82%) 22/112 (20%) < 0.001
Urine leukocytes > 50 × 106/L 115 57 (50%) 21/21 (100%) 36/94 (38%) < 0.001
Urine erythrocytes > 50 × 106/L 115 36/113 (32%) 11/21 (52%) 26/94 (28%) 0.04
Positive urine culture 117 24 (21%) 17/22 (77%) 7/95 (7%) < 0.001
Bacteremia 141 104 (74%) 15 (68%) 89/119 (75%) 0.52
Requiring ICU admission 141 40/139 (29%) 6/23 (26%) 34/116 (29%) 0.76
Relapse# 144 5 (3%) 1 (5%) 4 (3%) 0.57
Death** 144 10 (7%) 1 (5%) 9 (7%) 1

ATSI = Aboriginal or Torres Strait Islander; ICU = intensive care unit. For age, the median and interquartile range is presented. For all other variables, the absolute number (percentage) is presented.

*

If documented in the medical record.

Serum creatinine ≥ 150 μmol/L documented before the presentation.

Receiving any ongoing treatment of a chronic lung condition.

§

Use of immunosuppressive agents, including corticosteroids, chemotherapy or immunomodulatory therapies.

Pathologically confirmed malignant neoplasm.

Dysuria, urgency, frequency, retention, or incontinence.

#

Clinical deterioration in association with a positive culture for Burkholderia pseudomallei.

**

Death due to melioidosis within 90 days of hospitalization.